Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MPN Advances Day 2019 | Future therapies for MF: pacritinib, momelotinib, fedratinib & other pathways

Speaking at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK, Ruben Mesa, MD, FACP, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses the latest treatments in development for myelofibrosis, as well as understanding of the disease. He highlights JAK inhibitors, as well as other pathway inhibitors such as LSD1, BET, MDM2 and TGF-β.